Citations

Showing 10 of 108094 citations.

Vascular Collagen Type-IV in Hypertension and Cerebral Small Vessel Disease
Kumar, Apoorva A. , Yeo, Natalie , Whittaker, Max , Attra, Priya , Barrick, Thomas R. , Bridges, Leslie, Dickson, Dennis W. , Esiri, Margaret M. , Farris, Chad W. , Graham, Delyth , Lin, Wen-Lang , Pereira, Anthony , Perry, Gregory , Agtmael, Tom Van , Zamboni, Giovanna , Hainsworth, Atticus H. , Meijles, Daniel N , Pereira, Anthony C , Rosene, Douglas L , Shtaya, Anan B , Van Agtmael, Tom , Zamboni, Giovanna , Hainsworth, Atticus H , Dickson, Dennis W , Perry, Gregory

Mayo Clinic

Stroke | October 7, 2022 | Volume: 53 | Issue: 12 | Pages: 3696-3705

10.1161/strokeaha.122.037761 | PMID 36205142 Get It

Background: Cerebral small vessel disease (SVD) is common in older people and causes lacunar stroke and vascular cognitive impairment. Risk factors include old age, hypertension and variants in the genes COL4A1/COL4A2 encoding collagen alpha-1(IV) and alpha-2(IV), here termed collagen-IV, which are core components of the basement membrane. We tested the hypothesis that increased vascular collagen-IV associates with clinical hypertension and with SVD in older persons and with chronic hypertension in young and aged primates and genetically hypertensive rats. Methods: We quantified vascular collagen-IV immunolabeling in small arteries in a cohort of older persons with minimal Alzheimer pathology (N=52; 21F/31M, age 82.8±6.95 years). We also studied archive tissue from young (age range 6.2–8.3 years) and older (17.0–22.7 years) primates ( M mulatta ) and compared chronically hypertensive animals (18 months aortic stenosis) with normotensives. We also compared genetically hypertensive and normotensive rats (aged 10–12 months). Results: Collagen-IV immunolabeling in cerebral small arteries of older persons was negatively associated with radiological SVD severity (ρ: −0.427, P =0.005) but was not related to history of hypertension. General linear models confirmed the negative association of lower collagen-IV with radiological SVD ( P <0.017), including age as a covariate and either clinical hypertension ( P <0.030) or neuropathological SVD diagnosis ( P <0.022) as fixed factors. Reduced vascular collagen-IV was accompanied by accumulation of fibrillar collagens (types I and III) as indicated by immunogold electron microscopy. In young and aged primates, brain collagen-IV was elevated in older normotensive relative to young normotensive animals ( P =0.029) but was not associated with hypertension. Genetically hypertensive rats did not differ from normotensive rats in terms of arterial collagen-IV. Conclusions: Our cross-species data provide novel insight into sporadic SVD pathogenesis, supporting insufficient (rather than excessive) arterial collagen-IV in SVD, accompanied by matrix remodeling with elevated fibrillar collagen deposition. They also indicate that hypertension, a major risk factor for SVD, does not act by causing accumulation of brain vascular collagen-IV.
Association between basic life support and survival in sports-related sudden cardiac arrest: a meta-analysis
Michelland, Laurianne , Bougouin, Wulfran , Broek, Mark Van Der, Anys, Soraya, Perier, Marie‐Cécile, Cariou, Alain , Empana, Jean‐Philippe , Marijon, Éloi , Jouven, Xavier , Jabre, P. , Murad, Mohammad H, Empana, Jean Philippe , Marijon, Eloi , Jabre, Patricia , Murad, M. Hassan , Prokop, Larry J.

Mayo Clinic

European Heart Journal | October 7, 2022 | Volume: 44 | Issue: 3 | Pages: 180-192

10.1093/eurheartj/ehac586 | PMID 36285872 Get It

Abstract Aims To evaluate the association of basic life support with survival after sports-related sudden cardiac arrest (SR-SCA). Methods and results In this systematic review and meta-analysis, a search of several databases from each database inception to 31 July 2021 without language restrictions was conducted. Studies were considered eligible if they evaluated one of three scenarios in patients with SR-SCA: (i) bystander presence, (ii) bystander cardiopulmonary resuscitation (CPR), or (iii) bystander automated external defibrillator (AED) use and provided information on survival. Risk of bias was evaluated using Risk of Bias in Non-randomized Studies of Interventions. The primary outcome was survival at the longest follow up. The meta-analysis was conducted using the random-effects model. The Grading of Recommendations Assessment, Development, and Evaluations (GRADE) approach was used to rate certainty in the evidence. In total, 28 non-randomized studies were included. The meta-analysis showed significant benefit on survival in all three groups: bystander presence [odds ratio (OR) 2.55, 95% confidence interval (CI) 1.48–4.37; I2 = 25%; 9 studies—988 patients], bystander CPR (OR 3.84, 95% CI 2.36–6.25; I2 = 54%; 23 studies—2523 patients), and bystander AED use (OR 5.25, 95% CI 3.58–7.70; I2 = 16%; 19 studies—1227 patients). The GRADE certainty of evidence was judged to be moderate. Conclusion In patients with SR-SCA, bystander presence, bystander CPR, and bystander AED use were significantly associated with survival. These results highlight the importance of witness intervention and encourage countries to develop their first aid training policy and AED installation in sport settings.
Comparative Analysis of Early Outcomes and Complications of PSO Among Neurosurgeons and Orthopedic Surgeons
Neifert, Sean N. , Chapman, Emily , Price, Gabrielle A. , Hwang, Songhon, McNeill, Ian Thomas , Deutsch, Brian C. , Martini, Michael L. , Shuman, William H. , Steinberger, Jeremy M. , Caridi, John M.

Mayo Clinic

Clinical Spine Surgery | October 6, 2022 | Volume: 36 | Issue: 5 | Pages: E174-E179

10.1097/bsd.0000000000001401 | PMID 36201848 Get It

Study Design: Retrospective comparative cohort study using the National Surgical Quality Improvement Program. Objective: The aim of this study was to evaluate trends in the annual number of PSOs performed, describe the patient populations associated with each cohort, and compare outcomes between specialties. Summary of Background Data: Pedicle subtraction osteotomies (PSO) are complex and advanced spine deformity surgical procedures performed by neurosurgeons and orthopedic surgeons. Though both sets of surgeons can be equally qualified and credentialed to perform a PSO, it is possible that differences in training and exposure could translate into differences in patient management and outcomes. Methods: Patients that underwent lumbar PSO from 2005 to 2014 in the American College of Surgeons-National Surgical Quality Improvement Program registry were identified. Relevant demographic, preoperative comorbidity, and postoperative 30-day complications were queried and analyzed. The data was divided into 2 cohorts consisting of those patients who were treated by neurosurgeons versus orthopedic surgeons. Additional data from the Scoliosis Research Society Morbidity and Mortality database was queried and analyzed for comparison. Results: Demographic and comorbidity factors were similar between the neurosurgery and orthopedic surgery cohorts, except there were higher rates of hypertension among orthopedic surgeon-performed PSOs (65.66% vs. 48.67%, P=0.004). Except for 2012, in every year queried, orthopedic surgeons reported more PSOs than neurosurgeons. In patients who underwent lumbar fusion surgery, there was a higher rate of PSOs if the surgery was performed by an orthopedic surgeon (OR 1.7824, 95% CI: 1.4017–2.2665). The incidence of deep vein thrombosis after PSOs was higher for neurosurgery compared with orthopedic surgery (8.85% vs. 1.20%, P=0.004). However, besides deep vein thrombosis, there were no salient differences in surgical complication rates between neurosurgeon-performed PSOs and orthopedic surgeon-performed PSOs. Conclusions: The number of PSO procedures performed by neurosurgeons and orthopedic surgeons has increased annually. Differences in outcomes between neurosurgeons and orthopedic surgeons suggest an opportunity for wider assessment and alignment of adult spinal deformity surgery exposure and training across specialties.
Remotely Guided Immunobots Engaged in Anti‐Tumorigenic Phenotypes for Targeted Cancer Immunotherapy
Dogan, Nihal Olcay , Ceylan, Hakan , Suadiye, Eylül , Sheehan, Devin , Aydın, Aslı , Yasa, Immihan Ceren , Richter, Gunther , Sitti, Metin , Richter, Gunther , Sitti, Metin , Ceylan, Hakan , Wild, Anna‐Maria

Mayo Clinic

Small | October 6, 2022 | Volume: 18 | Issue: 46 | Pages: No page available

10.1002/smll.202204016 | PMID 36202751 Get It

Abstract Building medical microrobots from the body's own cells may circumvent the biocompatibility concern and hence presents more potential in clinical applications to improve the possibility of escaping from the host defense mechanism. More importantly, live cells can enable therapeutically relevant functions with significantly higher efficiency than synthetic systems. Here, live immune cell‐derived microrobots from macrophages, i.e., immunobots , which can be remotely steered with externally applied magnetic fields and directed toward anti‐tumorigenic (M1) phenotypes, are presented. Macrophages engulf the engineered magnetic decoy bacteria , composed of 0.5 µm diameter silica Janus particles with one side coated with anisotropic FePt magnetic nanofilm and the other side coated with bacterial lipopolysaccharide (LPS). This study demonstrates the torque‐based surface rolling locomotion of the immunobots along assigned trajectories inside blood plasma, over a layer of endothelial cells, and under physiologically relevant flow rates. The immunobots secrete signature M1 cytokines, IL‐12 p40, TNF‐α, and IL‐6, and M1 cell markers, CD80 and iNOS, via toll‐like receptor 4 (TLR4)‐mediated stimulation with bacterial LPS. The immunobots exhibit anticancer activity against urinary bladder cancer cells. This study further demonstrates such immunobots from freshly isolated primary bone marrow‐derived macrophages since patient‐derivable macrophages may have a strong clinical potential for future cell therapies in cancer.
Demographic Representation Among Speakers and Program Committee Members at the IDWeek Conference, 2013–2021
Marcelin, Jasmine R , Khazanchi, Rohan , Lyden, Elizabeth, Florez, Narjust , Kullar, Ravina , Ristagno, Elizabeth H. , group, the Introduction of Speakers at IDWeek Events Observing for Unconscious Bias over Time (INSIDE-OUT) study, Rajapakse, Nipunie , Patel, Megha, Miller, Amy M. , Oeltjen, Erin N, Semaj, Sophie, Sramek, Kyle T, Lindeman, Christopher J, Daubach, Eric C., Akinmoladun, Oladapo O, Wurtz, Paul J, Marcelin, Jasmine , Lyden, Elizabeth , Cawcutt, Kelly , Ha, David R , Florez, Narjust , group, the Introduction of Speakers at IDWeek Events Observing for Unconscious Bias over Time (INSIDE-OUT) study, Patel, Megha, Akinmoladun, Oladapo O., Yang, Yuhong

Mayo Clinic

Clinical Infectious Diseases | October 6, 2022 | Volume: 76 | Issue: 5 | Pages: 897-904

10.1093/cid/ciac816 | PMID 36208201 Get It

AbstractBackgroundIn 2016, the IDWeek program committee was charged with ensuring gender equity in speaker sessions. Whether this charge also resulted in more opportunities for historically underrepresented speakers is unknown.MethodsWe conducted a retrospective analysis of trends in the demographic composition of IDWeek speakers and program committee members between 2013 and 2021. We used descriptive statistics to summarize data, χ2 tests to compare speaker demographics between 2013–2016 (before 2016) and 2017–2021 (after 2016), and Cochran–Armitage tests for trend. Each speaker slot was considered an independent event.ResultsA total of 5482 speaker slots were filled by 3389 individuals from 2013 to 2021. There was a linear increase in female speakers from 38.6% in 2013 to 58.4% in 2021 (P &lt; .001). The proportion of white speakers decreased overall from 84.9% in 2013 to 63.5% in 2021. Compared with white speakers, more slots were filled by Asian speakers after 2016 versus before 2016 (20.1% vs 14.8%, respectively; P &lt; .001). Program committee members from 2013–2021 were &gt;80% non-Hispanic white; &lt;5% of committee members identified as black, American Indian, Alaska Native, Native Hawaiian, Pacific Islander, or Hispanic. More program committee slots were filled by women after 2016 than before 2016 (52.7% vs 33.9%; P = .004).ConclusionsIntentional consideration of gender equity by the program committee was associated with equitable gender representation of invited speakers at IDWeek after 2016. Gradually, the proportions of IDWeek speakers from historically excluded racial/ethnic approached their respective proportions in the IDSA membership. White speakers remained overrepresented relative to membership proportions until 2021, and gaps in program committee racial/ethnic demographic representation highlights opportunities for continued inclusion, diversity, access, and equity at IDWeek.
A Consistent Lack of Consistency in Defining the Acute and Chronic Phases of Peyronie's Disease: A Review of the Contemporary Literature
Piraino, Javier , Chaudhary, Hira, Ames, Kyle, Okoye, Frederick , Sterling, Matthew, Clavell-Hernández, Jonathan, Levine, Laurence A. , Ziegelmann, Matthew , Ziegelmann, Matthew J

Mayo Clinic

Sexual Medicine Reviews | October 6, 2022 | Volume: 10 | Issue: 4 | Pages: 698-713

10.1016/j.sxmr.2022.08.001 | PMID 36210095 Get It

Abstract Introduction Treatment recommendations for Peyronie's Disease (PD) differ based on whether a patient is in the acute/active versus chronic/stable phase of the disease, yet there are no agreed upon criteria for defining these clinical entities. Objectives To review the criteria used to define acute and chronic phase PD in modern PD intervention studies Methods We performed a search engine review to identify indexed publications for PD intervention studies and review articles / meta-analyses from the year 2011-2020. Outcomes results were catalogued and summarized across articles. As a result of the substantial heterogeneity of outcome measures and follow-up intervals, meta-analytic techniques were not applied to the data analysis. Results We identified a total of 104 studies that met inclusion criteria and had available information for review (n = 79 primary intervention studies; n = 25 review articles/meta-analyses/guidelines). Among the queried studies, we were unable to identify a consensus with respect to the criteria used to define acute and chronic phases of PD. 33% of primary intervention studies did not specifically define their criteria for acute and chronic phase PD, despite referencing these populations as part of the inclusion criteria in many instances. Studies used heterogenous criteria including total symptom duration, duration of “stable” symptoms, and presence/absence of pain. Conclusion Due to varying definitions across the literature, we were unable to create a standardized definition of acute and chronic phase Peyronie's in terms of time. Our findings emphasize the need for greater consensus in defining the treatment cohorts with future studies that assess treatment for men with PD.
Adapting investigational drug services during a pandemic: Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group
Finnes, Heidi D. , Child, Berrie, DeFrates, Sean, Kinsman, Katharine, Thorne, Andrew, Lockhorst, Robin, Urmanski, Angela, Amin, Sapna, Barr, Hallie, Baviskar, Sunanda, Beckman, Carrie , Chow, Nicholas , Derba, Megan, Erickson, Marsha K., Hennes, Emily R , Heisey, Heather D., Limvorasak, Suwicha , Luckritz, Todd, Mays, Theresa A., Nzelibe, Chukwuemeka N, Romanowski, Tracy, Smith, Camille M. , Tesoro, Debra, Toeniskoetter, Katelyn, Voytilla, Krista, Lentz, Sarah, Murphy, Jennifer, Lau, Rebecca

Mayo Clinic

American Journal of Health-System Pharmacy | October 6, 2022 | Volume: 80 | Issue: 1 | Pages: e67-e73

10.1093/ajhp/zxac267 | PMID 36200957 Get It

Avoiding Checkmate—Playing Chess With Cancer
Desai, Aakash , Desai, Aakash P

Mayo Clinic

JAMA Oncology | October 6, 2022 | Volume: 8 | Issue: 12 | Pages: 1740

10.1001/jamaoncol.2022.4422 | PMID 36201179 Get It

The author of this essay uses his experience learning the complex planning and strategies of chess in childhood to illustrate the importance of informed strategy in the treatment of patients with cancer.
Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status
Abeykoon, Jithma P. , Ravindran, Aishwarya , Ruan, Gordon , Dasari, Surendra , King, Rebecca L. , Rummage, Claire, Zanwar, Saurabh , Acosta-Medina, Aldo M., Tobin, W. Oliver , Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Acosta‐Medina, Aldo A. , Ruan, Gordon J , Tobin, W Oliver , Vassallo, Robert , Ravindran, Aishwarya , Ryu, Jay H , Acosta-Medina, Aldo A , Rech, Karen L. , Young, Jason R. , Morlote, Diana M. , Shah, Meera , Bennani, N. Nora , Koster, Matthew J. , Witzig, Thomas E. , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

JAMA Oncology | October 6, 2022 | Volume: 8 | Issue: 12 | Pages: 1816

10.1001/jamaoncol.2022.4432 | PMID 36201194 Get It

ImportanceRosai-Dorfman disease (RDD) is a rare histiocytic neoplasm with recent studies showing alterations in the MAPK pathway, most commonly in the KRAS and MEK genes in about 40% of patients. Reports on the use of MEK-inhibitor therapy in RDD have been limited to small case studies. There are no approved treatments for this neoplasm, and therefore patients with RDD need efficacious treatments.ObjectiveTo study the outcomes after treatment with cobimetinib based on MAPK pathway alterations in patients with RDD.Design, Setting, and ParticipantsThis retrospective cohort study conducted at 2 tertiary care centers included patients with RDD who underwent treatment with cobimetinib between January 1, 2013, and December 1, 2021. Cobimetinib was administered at a dosage of 20 to 60 mg orally once daily as a single agent for 21 days in a 28-day cycle. Pathology was centrally reviewed. Response assessment was centrally conducted and was based on the established positron emission radiography response criteria used for clinical trials of targeted therapies in histiocytosis.Main Outcomes and MeasuresMain outcomes were overall response rate (ORR), progression-free survival (PFS), adverse events (AEs) of cobimetinib in the entire cohort, and ORRs and PFS based on MAPK pathway alterations in patients with RDD.ResultsA total of 16 patients (median [range] age at cobimetinib initiation, 57 [31-74] years; 11 [69%] women) were included in the study. The median follow-up duration was 19.0 months (95% CI, 8.4-27.8 months). The ORR was 63% (n = 10), including 5 complete responses and 5 partial responses. Somatic alterations in the KRAS or MEK genes were detected in 8 (50%) patients. Patients with KRAS or MEK alterations had significantly higher ORR (88% vs 38%; P = .03), deeper responses (complete responses among responders: 71% vs 0%; P = .002), and better PFS (at 1 year, 100% vs 29% were free from progression or death, respectively; P &amp;lt; .001) compared with those without such alterations. Grade 2 or higher AEs occurred in 12 (75%) patients, and 9 (56%) required dose reduction or temporary/permanent treatment discontinuation due to AEs.Conclusions and RelevanceIn this cohort study, treatment with cobimetinib was associated with positive outcomes in KRAS- or MEK-variant RDD. However, AEs requiring dose modifications were common.